Olumiant (baricitinib) oral tablets - first FDA approved Alopecia Areata treatment.
Alopecia areata is an autoimmune disorder. Alopecia areata patients experience hair loss (usually in patches) when their body’s immune system starts attacking its own hair follicles.
Olumiant is a Janus kinase (JAK) inhibitor. It was originally approved in 2018 for the treatment of rheumatoid arthritis. More recently, Olumiant is also used to treat certain Covid 19 patients.
Janus kinase (JAK) inhibitor works by counteracting or blocking an overactive immune system from causing excessive inflammation.
Over 30% of the test patients who received 4mg Olumiant achieved at least 80% scalp coverage at 36 months.
Full story at
https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
Hasson & Wong sponsored post - #1 hair clinic in Canada and Top 3 clinics of all time in the world according to HairSite’s patient statistics. For more info, visit: